For information concerning this clinical site, please contact Nymox at 800-936-9669.

Tucson, Arizona 85715

0 studies enrolling now · 2 studies all time

What they study most

Benign Prostatic Hyperplasia, Prostate Cancer

Studies at this site

• Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer — Completed
• Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) — Completed